NCT01816971: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone Before and After ASCT NDMM
Updated: Aug 9, 2022
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
KRd
This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from diving. Giving carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant may kill more cancer cells
Sponsor
University of Chicago
Collaborator
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01816971
Official Title: Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
First Posted: March 22, 2013
Click here to see details on ClinicalTrials.gov
Blood; 2020 Nov
Blood Cancer J; 2021 Feb
Drug: dexamethasone
Drug: carfilzomib
Drug: lenalidomide
Procedure: autologous hematopoietic stem cell transplantation
Other: laboratory biomarker analysis
Locations
United States, Illinois
United States, Massachusetts
United States, Missouri
United States, Tennessee
Canada, Ontario